^{99m}Tc -labelled Stealth[®] liposomal doxorubicin (Caelyx[®]) in glioblastomas and metastatic brain tumours

P Laverman^{*,1}, OC Boerman¹, G Storm² and WJG Oyen¹

¹Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; ²Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands

British Journal of Cancer (2002) **86**, 659–660. DOI: 10.1038/sj/bjc/6600093 www.bjcancer.com
© 2002 Cancer Research UK

Sir

We read with interest the article by Koukourakis *et al* (2000a) describing the use of radiolabelled Caelyx to study the accumulation of the polyethylene glycol (PEG)-liposomes in glioblastomas and metastatic brain tumours, and would like to take the opportunity to make some principal remarks regarding the applied radiolabelling procedure.

To facilitate imaging of the accumulation of the liposomes in the tumours, the authors labelled the liposomal formulation with technetium-99m-diethylenetriamine pentaacetic acid (^{99m}Tc -DTPA). This labelling method was described previously in more detail by the same group (Koukourakis *et al*, 1999). However, we have some major concerns about the labelling method and imaging protocol used in their studies (Koukourakis *et al*, 1999, 2000a,b).

The applied labelling method is based on the assumption that adding ^{99m}Tc -DTPA to the PEG-liposomes (in the Caelyx formulation) results in radiolabelled liposomes. This method, which has not been described in the literature before, is expected to yield an unstable radiolabelled product, since there is no driving force that will facilitate the hydrophilic ^{99m}Tc -DTPA to pass the lipid bilayer and entrap the radiolabel inside the liposome. Moreover, the described quality control method (Koukourakis *et al*, 1999, 2000a,b) does not discriminate between free ^{99m}Tc -DTPA and liposome-associated ^{99m}Tc -activity. The chromatographic method applied can distinguish between reduced $^{99m}\text{TcO}_2$ and unreduced $^{99m}\text{TcO}_4^-$, however, it is more essential to discriminate between liposome-associated ^{99m}Tc -activity and ^{99m}Tc -DTPA in the preparation. The proper way to examine this, would be to elute a sample of the radiolabelled liposomes on a gel permeation column as described previously (Dams *et al*, 2000; Harrington *et al*, 2001). The (radiolabelled) liposomes will elute with the void volume in the early fractions, whereas the non-liposome-associated radiolabel (both as ^{99m}Tc -DTPA, $^{99m}\text{TcO}_2$, and $^{99m}\text{TcO}_4^-$) will elute in later fractions.

Our attempts to reproduce the labelling method as described by Koukourakis *et al* (2000a) failed. Analysis of the labelling mixture by instant thin layer chromatography (ITLC) according to Koukourakis *et al* (2000a) showed the same results as described in their article, suggesting a labelling efficiency of approximately 80%. However, analysis on a Sephadex G25-column revealed that only 1% of the ^{99m}Tc activity was associated with the liposomes and the majority of the activity eluted in later fractions (Figure

1). This was confirmed by ITLC on silica strips in sodium citrate, a method to distinguish ^{99m}Tc -DTPA and ^{99m}Tc -liposomes described previously (Cao and Suresh, 2000).

Our second point of concern is the chosen time-point of imaging. The patients were imaged at 2 h after infusion of the liposomes (Koukourakis *et al*, 2000a). Harrington *et al* (2001) showed that clear visualization of solid tumours with ^{111}In -labelled long-circulating PEG-liposomes was achieved not earlier than 48–72 h after injection, due to the high blood background signal at earlier time-points. These findings are in line with our clinical study in patients with infectious or inflammatory disease, imaged with similar ^{99m}Tc -PEG-liposomes, labelled with ^{99m}Tc -hexamethylpropylene-amine-oxime (Dams *et al*, 2000). Therefore, it appears that the images showing liposome uptake in the tumours (Koukourakis *et al*, 2000a) represent the accumulation of ^{99m}Tc -DTPA, rather than uptake of the radiolabelled Caelyx. ^{99m}Tc -DTPA was used in the past for diagnosis of a disrupted blood–brain barrier in brain tumours, before the CT and MRI era (Hauser *et*

Figure 1 Elution profile of ^{99m}Tc -DTPA-Caelyx[®] (labelled according to Koukourakis *et al*, 1999) and ^{111}In -oxinate-Caelyx[®] (labelled according to Laverman *et al*, 2001) on a 10 ml Sephadex G25 column. A sample of 100 μl was applied. Twenty consecutive fractions of 1 ml were eluted with 5% glucose and the activity of each fraction was counted in a gamma-counter. Note that the radiolabelled liposomes elute in fractions 3–5, whereas the free radiolabel elutes in fractions 6–14.

*Correspondence: P Laverman; E-mail: p.laverman@nugen.azn.nl

al, 1970). Nowadays, ^{99m}Tc -DTPA is a well-known agent for evaluation of renal function. It is cleared rapidly and efficiently from the circulation by glomerular filtration. This might explain, for liposomes, the unusual, rapid accumulation of activity in the tumours. In our opinion, the authors should have performed, and shown – at least in some patients – a control ^{99m}Tc -DTPA scan, to rule out that the liposome scan represents free ^{99m}Tc -DTPA instead of radiolabelled Caelyx.

A better approach to label Caelyx would be the labelling with indium-111-oxine (^{111}In -oxine). This easy method will yield radio-labelled liposomes with good radiochemical yield (>80%) and

good *in vivo* stability (Laverman *et al*, 2001). An additional advantage is the longer physical half-life of ^{111}In , which enables the acquisition of delayed images and thus better visualization of the tumours (Harrington *et al*, 2001).

In summary, scintigraphic techniques are very helpful in investigating the *in vivo* distribution of (new) pharmaceuticals, but should only be performed using well-established labelling techniques and quality control methods. The results presented by Koukourakis *et al* (1999, 2000a,b) should therefore be interpreted with caution.

REFERENCES

- Cao Y, Suresh MR (2000) Bispecific MAb aided liposomal drug delivery. *J Drug Target* **8**: 257–266
- Dams ET, Oyen WJ, Boerman OC, Storm G, Laverman P, Kok PJ, Buijs WC, Bakker H, van der Meer JW, Corstens FH (2000) ^{99m}Tc -PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. *J Nucl Med* **41**: 622–630
- Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. *Clin Cancer Res* **7**: 243–254
- Hauser W, Atkins HL, Nelson KG, Richards P (1970) Technetium-99m DTPA: a new radiopharmaceutical for brain and kidney scanning. *Radiology* **94**: 679–684
- Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitsas N, Helidonis ES (1999) Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. *J Clin Oncol* **17**: 3512–3521
- Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, Karkavitsas N (2000a) High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. *Br J Cancer* **83**: 1281–1286
- Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulas V, Velidaki A, Archimandritis S, Karkavitsas NN (2000b) High intratumoural accumulation of stealth liposomal doxorubicin in sarcomas – rationale for combination with radiotherapy. *Acta Oncol* **39**: 207–211
- Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G (2001) Factors affecting the accelerated blood clearance of PEG-liposomes upon repeated injection. *J Pharmacol Exp Ther* **298**: 607–612

Reply: ^{99m}Tc -labelled Stealth liposomal doxorubicin (Caelyx[®]) in glioblastomas and metastatic brain tumours

MI Koukourakis*¹

¹Tumour and Angiogenesis Research Group, Department of Radiotherapy and Oncology, Democritus University of Thrace, PO Box 12, Alexandroupolis 68100, Greece

British Journal of Cancer (2002) **86**, 660–661. DOI: 10.1038/sj/bjc/6600094 www.bjcancer.com
© 2002 Cancer Research UK

Sir

In these previous studies we provided a simple method to label Caelyx by incubation of 5 mg of the ready-to-use solution with 20 mCi of ^{99m}Tc -DTPA. Instant thin layer chromatography (ITLC) suggested an 80% labelling (Koukourakis *et al*, 1999), which is also a result found by Dr Laverman and colleagues. As additional more sophisticated analysis, performed by the later research group, failed to confirm this finding, it was suggested that the tumour and body

imaging obtained in our studies is rather a result of ^{99m}Tc -DTPA and not of labelled liposomes.

^{99m}Tc -DTPA is currently used in the evaluation of renal function, and as well noted by Dr Laverman, this is rapidly cleared from the kidneys. Two hours following injection, the imaging quality of kidneys is really poor. ^{99m}Tc -DTPA can give good images of gliomas, probably as a result of the high tumour vascularization or even of the disrupted blood–brain barrier, which allows a net contrast between normal and abnormal brain. However, imaging of other tumours with ^{99m}Tc -DTPA is questionable.

*Correspondence: MI Kourakis; E-mail: targ@her.forthnet.gr